Granules India Shares Slump Despite Securing EIR from USFDA 

Shares of Granules India Ltd were trading in the red and almost 1% lower on 15 December despite the company announcing that it has received an Establishment Inspection Report (EIR) for its Hyderabad facility.

The company, a wholly owned subsidiary of Granules Life Sciences based in Hyderabad, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the first inspection, which took place from 28 July to 1 August 2025.

This approval shows that the facility complies with FDA quality standards and regulatory criteria. Granules Life Sciences manufactures both PFI and completed doses.

In addition, the corporation obtained the highest “A” rating in Climate Change, up two levels from the “B” rating in 2024. Furthermore, the company received a “B” rating in Water Security and a “B-” rating in Forests in the first declaration.

Last week, the company’s US step-down subsidiary, Granules Consumer Health, LLC, passed a GMP inspection by the FDA with zero observations.

In addition, two advanced Centres of Excellence were inaugurated at IIT Hyderabad’s Technology Research Park: the Ascelis Centre of Excellence for Peptide Development and Characterisation and the Granules Centre of Excellence for Particle Engineering.

At 12:55 pm, the shares of Granules India were trading 0.52% lower at Rs 571.50 on NSE. 

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

The post Granules India Shares Slump Despite Securing EIR from USFDA  appeared first on Equitypandit.